78471-43-9

Basic information

• Product Name: METHYL 4-BROMO-2-BROMOMETHYL-BENZOATE
• Synonyms: METHYL 4-BROMO-2-BROMOMETHYL-BENZOATE;1-(4-BROMO-2-(BROMOMETHYL)PHENYL)ETHANONE;4-BroMo-2-broMoMethyl-benzoic acid Methyl ester;Benzoic acid, 4-broMo-2-(broMoMethyl)-, Methyl ester;Methyl 2-bromomethyl-4-bromobenzoate
• CAS NO: 78471-43-9
• Molecular Formula: C₉H₈Br₂O₂
• Molecular Weight: 307.97
• Mol File: 78471-43-9.mol
• Article Data: 62

Chemical Properties

• Melting Point: 76-78℃
• Boiling Point: 364.267 °C at 760 mmHg
• Flash Point: 174.103 °C
• Appearance: /
• Density: 1.78 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: METHYL 4-BROMO-2-BROMOMETHYL-BENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 4-BROMO-2-BROMOMETHYL-BENZOATE(78471-43-9)
• EPA Substance Registry System: METHYL 4-BROMO-2-BROMOMETHYL-BENZOATE(78471-43-9)

Safety Data

• RIDADR: UN 3261 8/PG III
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 78471-43-9(Hazardous Substances Data)

Usage

Uses

Methyl 4-bromo-2-(bromomethyl)benzoate is used as pharmaceutical intermediate.

InChI:InChI=1/C9H8Br2O2/c1-13-9(12)8-3-2-7(11)4-6(8)5-10/h2-4H,5H2,1H3

Upstream product

• 67-56-1 methanol 
• 68837-59-2 4-bromo-2-methylbenzoic acid 
• 99548-55-7 4-bromo-2-methyl-benzoic acid methyl ester 
• 7440-33-7 tungsten 

Downstream Products

• 861605-94-9 2-phenoxy-4-bromobenzoic acid 
• 918330-02-6 5-bromo-2-phenylisoindolin-1-one 
• 848464-88-0 (S)-3-(5-Bromo-1-oxo-1,3-dihydro-isoindol-2-yl)-pyrrolidine-1-carboxylic acid methyl-[(S)-1-(3-phenyl-propyl)-pyrrolidin-3-yl]-amide 

Relevant articles and documents

Discovery and biological profile of isoindolinone derivatives as novel metabotropic glutamate receptor 1 antagonists: A potential treatment for psychotic disorders

We describe here the discovery and biological profile of a series of isoindolinone derivatives as developed mGluR1 antagonists. Our combined strategy of rapid parallel synthesis and conventional medicinal optimization successfully led to N-cyclopropyl 22 and N-isopropyl isoindolinone analogs 21 and 23 with improved in vivo DMPK profiles. Moreover the most advanced analog 23 showed an oral antipsychotic-like effect at a dose of 1 mg/kg in an animal model.

PROCESSES FOR PREPARING 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE

Provided herein are processes for preparing 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide.

PFKFB3 INHIBITORS AND THEIR USES

This disclosure relates to new phthalimide and isoindolinone derivatives and other PFKFB3 inhibitors for use in the treatment of diseases. The invention further relates to pharmaceutical compositions containing such PFKFB3 inhibitors, methods of preparation thereof, methods for their use as therapeutic agents, and methods of preparation of a medicament for use in therapy, as well as kits and other inventiions comprising such PFKFB3 inhibitors. These PFKFB3 inhibitors are useful for the treatment and prophylaxis of cancer, neurodegenerative diseases, autoimmune diseases, inflammatory disorders, multiple sclerosis, metabolic diseases, inhibition of angiogenesis and other diseases and conditions, where the modulation of PFKFB3 and/or PFKFB4 has beneficial effect as well as neuroprotection.